Total lesion glycolysis of primary tumor and lymphnodes is a strong predictor for development of distant metastases in oropharyngeal carcinoma patients with independent validation in automatically delineated lesions. [PDF]
Zschaeck S +20 more
europepmc +1 more source
Prognostic value of maximum standard uptake value, metabolic tumor volume, and total lesion glycolysis of 18F-FDG PET/CT in patients with renal carcinoma: A protocol for systematic review and meta analysis. [PDF]
Xuan D +5 more
europepmc +1 more source
Analysis of Molecular Imaging Biomarkers Derived from [18F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [225Ac]Ac-PSMA-617-Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy. [PDF]
Burgard C +11 more
europepmc +1 more source
Significance of Metabolic Tumor Volume and Total Lesion Glycolysis Measured Using ¹⁸F-FDG PET/CT in Locally Advanced and Metastatic Gallbladder Carcinoma. [PDF]
Chun YJ +7 more
europepmc +1 more source
Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in lymph node metastases and risk stratification of endometrial carcinoma. [PDF]
Liu DD +7 more
europepmc +1 more source
Evaluation of lobar lymph node metastasis in non-small cell lung carcinoma using modified total lesion glycolysis. [PDF]
Dejima H +7 more
europepmc +1 more source
Total lesion glycolysis on FDG-PET/CT before salvage surgery predicts survival in laryngeal or pharyngeal cancer. [PDF]
Suzuki H +7 more
europepmc +1 more source
A novel biomarker, active whole skeletal total lesion glycolysis (WS-TLG), as a quantitative method to measure bone metastatic activity in breast cancer patients. [PDF]
Koizumi M, Motegi K, Umeda T.
europepmc +1 more source
Prognostic Value of Baseline and Interim Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT in Patients with Follicular Lymphoma. [PDF]
Liang JH +11 more
europepmc +1 more source
Pre-Therapeutic Total Lesion Glycolysis on [18F]FDG-PET Enables Prognostication of 2-Year Progression-Free Survival in MALT Lymphoma Patients Treated with CD20-Antibody-Based Immunotherapy. [PDF]
Mayerhoefer ME +8 more
europepmc +1 more source

